With Sanofi’s Lixisenatide CV Data, Another GLP-1 Heads To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to refile the once-daily GLP-1 receptor agonist in the U.S. in the third quarter following the completion of a cardiovascular outcomes trial that showed the drug was non-inferior to placebo.